✦ LIBER ✦

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

✍ Scribed by Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 488 KB
Volume: 25
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.23040

No coin nor oath required. For personal study only.

✦ Synopsis

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagnosed de novo patients, subjects undergoing drug withdrawal, and patients under pharmacological therapy. These groups were compared to age-matched control subjects. Anandamide levels in untreated patients were more than doubled as compared to controls. However, chronic dopaminergic replacement restored control anandamide levels. Abnormal anandamide increase might reflect a compensatory mechanism occurring in course of PD, aimed at normalizing dopamine depletion.

📜 SIMILAR VOLUMES

Onset of dyskinesia with adjunct ropinir

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

✍ Ray L. Watts; Kelly E. Lyons; Rajesh Pahwa; Kapil Sethi; Matthew Stern; Robert A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24hour prolonged-release (n 5 104) in PD patients not optimally controll

Study of istradefylline in patients with

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

✍ Robert A. Hauser; Lisa M. Shulman; Joel M. Trugman; John W. Roberts; Akihisa Mor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 1 views

## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A~2A~ receptor a

A comparison of sumanirole versus placeb

A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease

✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.

Effects of bilateral stimulation of the

Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations

✍ Karen Østergaard; Niels Sunde; Erik Dupont 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

We present the efficacy and side effects of bilateral deep brain stimulation (DBS) of the subthalamic nuclei (STN) performed with a more simplified surgical procedure than described by the Grenoble group. A consecutive series of 26 patients with advanced and levodopa-responsive Parkinson's disease a

Oral solution of levodopa ethylester for

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

✍ Ruth Djaldetti; Rivkah Inzelberg; Nir Giladi; Amos D. Korczyn; Yehudit Peretz-Ah 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral

Randomized trial of tolcapone versus per

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),